Our extrafine formulation is used in Trimbow®️ (beclometasone / formoterol / glycopyrronium) and Fostair®️ (beclometasone / formoterol).

When left untreated, small airways disease can have serious clinical consequences for people living with asthma or COPD.2,3 Timely optimisation of treatment for symptomatic patients is essential,3,4 and therapies targeting the small airways may be a promising option for both asthma and COPD.3,5

Learn more Watch video

*In a prospective cohort study of patients with asthma (N=773) and an observational study of patients with COPD (N=202); symptomatic COPD defined as CAT score ≥10.1,2

Extrafine particles (<2 μm) are potentially compatible with deep lung penetration6 and can reach previously suboptimally treated areas of the small airways.7–9

Learn more

At Chiesi, we offer the only portfolio of products with an extrafine formulation, available in a range of devices and strengths, designed to reach and treat the small airways.7,9–24

Learn more